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Abstract. The high affinity nerve growth factor (NGF) NGF 
receptor, p75NTR, is a member of the tumor necrosis factor (TNF) 
receptor superfamily that shares a conserved intracellular 
death domain capable of inducing apoptosis and suppressing 
growth in prostate epithelial cells. Expression of this receptor 
is lost as prostate cancer progresses and is minimal in estab-
lished prostate cancer cell lines. We aimed to verify the role 
of p75NTR in the azacitidine-mediated antitumor effects on 
22Rv1 and PC3 androgen-independent prostate cancer cells. 
In the present study, we reported that the antiproliferative and 
pro-apoptotic effects of 5-azacytidine (azacitidine) were more 
marked in the presence of physiological concentrations of 
NGF and were reduced when a blocking p75NTR antibody or the 
selective p75NTR inhibitor, Ro 08-2750, were used. Azacitidine 
increased the expression of p75NTR without interfering with the 
expression of the low affinity NGF receptor TrkA and induced 
caspase 9-dependent caspase 3 activity. Taken together, our 
results suggest that the NGF network could be a candidate for 
future pharmacological manipulation in aggressive prostate 
cancer.
Introduction
Prostate cancer (PCa) is one of the most common malignan-
cies in men (1). This tumor is androgen-dependent and is 
treated using surgery, radiotherapy and hormone therapy (2). 
However, PCa frequently progresses into a hormone-
independent, highly aggressive and invasive disease (3) 
presenting with multiple drug resistance. This neoplasia is 
also the most common malignancy in which the chromo-
some 17q21 is segregated (4-6) suggesting that genes located 
in the immediate vicinity of 17q21 can be important in PCa 
development/progression (5). p75NTR is a 75-kDa glycopro-
tein receptor that belong to the tumor necrosis factor (TNF) 
receptor superfamily and binds mainly to nerve growth factor 
(NGF) and has structural and sequential similarity to the TNF 
receptor (7). Notably, the human p75NTR gene locus has been 
mapped distal to 17q21-q22 (6). The prostate gland is one of 
the most abundant sources of NGF controlling cell prolifera-
tion and apoptosis (8,9). However, p75NTR is progressively lost 
during the progression of PCa (10-12). Loss of expression of 
p75NTR protein is correlated with increased Gleason's score of 
organ-confined pathological prostate tissues (12-14), and is 
completely absent in prostate tumor cells derived from metas-
tases (11). The re-expression of p75NTR was previously shown 
in PCa to retard cell cycle progression by inducing accumula-
tion of cells in the G1 phase with a concomitant reduction in 
cells in the S phase thus inducing apoptosis (15) and reverting 
androgen-independent growth (16). p75NTR can be upregulated 
by prolonged treatment with NGF (17) or GnRH treatment (18) 
indicating epigenetic mechanisms of protein expression.
DNA hypermethylation plays an important role in the 
downregulation of genes important for cell death in PCa. 
Demethylating agents have been shown to prevent tumori-
genesis and delay androgen-independent disease (19,20) in a 
TRAMP mouse model of PCa as well as to revert androgen 
independence (19,21,22) and chemoresistance in prostate 
tumor cells (23).
In the present study, we demonstrated that azacitidine 
treatment induced a dose-dependent increase in p75NTR expres-
sion. This was in agreement with a recent report showing that 
azacitidine and estrogen treatment induced p75NTR (24) in 22rv1 
cells. Blocking NGF antibodies or specific p75NTR inhibitors 
reverted this effect. Taken together, our results suggest that the 
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NGF network could be a candidate for future pharmacological 
manipulation in PCa therapy.
Materials and methods
Reagents. All the materials for the tissue culture were 
purchased from EuroClone S.p.A. (Milan, Italy). Antibodies: 
Bcl-2 (sc-509), Bax (N20) (sc-493), Bad (C20) (sc-943), 
p-Bad ser112 (sc-7998), Bcl-xL (H2) (sc-8392), TrkA (C20) 
(sc-20537), p-TrkA (E6) (sc-8058), p75NTR (H92) (sc-5634), 
TRADD (A-5) (sc46653), RIP (H207) (sc 7881), TRAF2 (D-3) 
(sc-136997), DR4 (C20) (sc-6823) and DR5 (N19) (sc-7192) 
were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA, uSA). DNMT1, DNMAT3a and DNMT3b antibodies 
were purchased from BioCarta LLC (San Diego, CA, uSA). 
Plasticware was obtained from Nunc (Roskilde, Denmark). 
Azacitidine (vidaza®) was obtained from Celgene Corporation 
(Summit, NJ, uSA). The p38 MAPK inhibitor SB202190 and 
ibuprofen were purchased from Sigma-Aldrich Italy (Milan, 
Italy). Ro 08-2750, a selective p75NTR inhibitor, was purchased 
from Tocris Bioscience (Bristol, uK).
Cell lines. Two aggressive PCa models (PC3 and 22rv1 cell 
lines) were obtained from the American Tissue Culture 
Collection (ATCC; Rockville, MD, uSA) and DSMZ 
(Braunschweig, Germany), respectively, and were grown as 
recommended.
Growth assays. Cells were seeded at a density of 2x104 cells/ml 
into 24-well plates. Cells were left to attach and grow in 5% 
FCS and Dulbecco's modified Eagle's medium (DMEM). 
Next, the cells were cultured under appropriate experimental 
conditions. Morphological controls were performed every 
day with an inverted phase-contrast photomicroscope (Nikon 
Diaphot, Tokyo, Japan) before cell trypsinization and counting 
by the NucleoCounter™ NC-100 automated cell counter 
system (Chemotec, Gydevang, Denmark). The effect on cell 
proliferation was measured by taking the mean cell number 
with respect to the controls over time for the different treat-
ment groups.
Cell cycle and apoptosis analysis. Adherent cells were tryp-
sinized, pooled with the culture supernatant containing the 
apoptotic cells already detached from the dish and centrifuged. 
Cells (1x106) were washed in phosphate-buffered saline (PBS) 
and fixed for 30 min by the addition of 1 ml of 70% ethanol. 
Apoptosis and cell cycle analyses were performed using the 
Tali Cell Cycle kit and the Tali apoptosis kit, Annexin v-Alexa 
Fluor 488 and propidium iodide-based staining (Life 
Technologies Italia, Monza, Italy). Apoptosis was further 
confirmed by cytofluorimetric analysis following the manu-
facturer's instructions. Stained cells were then measured on a 
Tali Image-Based Cytometer. Caspase 8 and -9 activities were 
evaluated using enzymatic assays from GenScript (Piscataway, 
NJ, uSA).
Western blot analysis. Cells (1x106) were washed with 
cold PBS and immediately lysed with 100 µl of lysis buffer 
(50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 1% 
Triton x-100, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 1 mM 
sodium orthovanadate, 30 mM p-nitrophenyl phosphate, 
10 mM sodium pyrophosphate, 1 mM phenylmethylsulfonyl 
fluoride, 10 µg/ml aprotinin and 10 µg/ml leupeptin). Cell 
lysates were electrophoresed in 7% SDS-PAGE, and separated 
proteins were transferred to a nitrocellulose membrane and 
probed with the appropriate antibodies as indicated.
In vivo treatments. Male CD1 nude mice (Charles River, 
Milan, Italy) were maintained under the guidelines established 
by our institution (university of L'Aquila, Medical School and 
Science and Technology School Board Regulations, complying 
with the Italian government regulation no. 116, January 27, 
1992, for the use of laboratory animals). All mice received s.c. 
flank injections of 1x106 PC3 and 22v1 cells. Tumor growth 
was assessed by a bi-weekly measurement of tumor diameters 
with a vernier calliper (length x width). Tumor weight was 
calculated as previously indicated (22). Treatments were 
started when tumor volumes reached ~80 mm3 (day 0) and 
were stopped after 28 days. Mice were grouped as follows: 
group 1, 10 mice received intraperitoneal (i.p.) injections of 
100 l PBS for a consecutive 7 days; group 2: 10 mice received 
i.p. injections of 100 l of azacitidine (Aza-CR) (0.8 mg/kg) 
for a consecutive 7 days. Tumors were fixed in paraformalde-
hyde for hystochemical and immunohystochemical analyses. 
Indirect immunoperoxidase staining of tumor xenografts was 
performed on paraffin-embedded 4-µm tissue sections. Briefly, 
the sections were incubated with the primary antibodies over-
night at 4˚C. Next avidin-biotin assays were carried out using 
the vectastain Elite kit (vector Laboratories, Burlingame, CA, 
uSA). Mayer's hematoxylin was used as a nuclear counterstain.
Statistical analysis. Continuous data are presented as the 
mean ± standard deviation (SD), and were compared using an 
umpired Student's t-test.
Results
Azacitidine restores the expression of p75NTR in PC3 and 
22rv1 cell models. In the present study, we demonstrated 
that the antiproliferative and pro-apoptotic effects induced 
by azacitidine at non-toxic concentrations (ranging between 
0.1 and 0.5 µM) were enhanced in the presence of 10 ng/ml 
NGF. We observed that NGF-induced growth inhibition was 
significantly higher when compared to data observed 
following treatment with the demethylating agent alone both 
in the PC3 (Fig. 1A) and 22rv1 cells (Fig. 1B). The addition 
of NGF triggered a significant and early apoptosis in both 
cell lines (Fig. 1C and D). Next, we analyzed the molecular 
arrangement induced by treatments using western blotting. We 
observed that expression of the high affinity p75NTR, but not 
expression of the low affinity receptor (TrkA) was increased 
after in vitro administration of azacitidine in a time-dependent 
manner in the PC3 and 22rv1 cells (Fig. 2A and B). As a 
positive control we used the androgen receptor (AR) which 
was widely demonstrated to be induced after azacitidine 
treatment (19,25). Western blot analyses were confirmed by 
immunocytochemical analyses (Fig. 2C) in the aggressive 
22rv1 cell line. The same tumor cell models were examined 
for expression levels of downstream components proximal 
to p75NTR (TRADD, RIP, DR4, DR5 and TRAF2) in both 
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the PC3 (Fig. 2D) and 22rv1 cells (Fig. 2E). Previously, 
we demonstrated that an intraperitoneal administration of 
azacitidine (vidaza®, 0.8 mg/kg for 7 consecutive days) in nude 
male mice subcutaneously inoculated with 22rv1 and PC3 cells 
was able to reduce tumor growth both in the PC3 and 22rv1 
xenograft models (22). In the present study, we demonstrated 
that reduction in the tumor mass after Aza-CR treatment was 
associated with p75NTR re-expression in vivo (Fig. 2F). Cell 
death was dependent on activation of the caspase 9 pathway 
which we also verified in vivo by analyzing FasL and TRAIL 
protein expression in the control and Aza-CR-treated tumors.
Azacitidine induces p75NTR-mediated cell death. It has been 
previously demonstrated that p38 MAPK activation, associ-
ated with ibuprofen treatment, is related to induction of 
p75NTR in PCa cells (26). Therefore, considering that the 
antitumor effects of azacitidine are associated with increased 
p38 MAPK activity necessary for the induction of cell cycle 
arrest in the G2 phase (27,28) and apoptosis (29), we verified 
whether the p38 MAPK inhibitor, SB202190, was able to 
prevent the induction of p75NTR using as a positive control, 
treatment with ibuprofen (1 µM). In agreement with the 
literature data, we demonstrated that: i) NGF reduced ERK 
activation, but not p38 MAPK (Fig. 3A), and ii) ibuprofen 
induced p75NTR (Fig. 3B) whereas p38 MAPK inhibition was 
able to reduce p75NTR expression (Fig. 3B). Similar results 
were obtained using P38 MAPK siRNA (data not shown) 
indicating that p75NTR expression was under p38 MAPK-
dependent epigenetic control. Thus, we analyzed the role of 
p75NTR in the azacitidine-induced cell death. For this aim we 
used a blocking antibody for p75NTR as well as the non-peptide 
antagonist of NGF, Ro 08-2750 [able to bind to the NGF dimer 
and inhibit selectively p75NTR at submicromolar concentra-
tions whereas both p75NTR and TrkA receptors were blocked 
at >5 µM (29)]. Both anti-NGF agents significantly increased 
the cell viability (Fig. 3C) and apoptosis (Fig. 3D) induced by 
co-treatment with azacitidine and NGF. Conversely the p75NTR 
induction by Aza-CR treatment was partial after SB202190 
(data not shown). Increased p75NTR observed after azacitidine 
treatment was related to increased expression of Bax and 
PARP cleavage as well as to reduced levels of Bcl2, xIAP and 
survivin (Fig. 4A) with caspase 8-dependent caspase 3 activa-
tion (Fig. 4B and C) in agreement with our in vivo effects (30).
Discussion
The low-affinity neurotrophin receptor p75NTR, a member of the 
tumor necrosis factor (TNF) receptor superfamily, is expressed 
in prostate gland (6-11) and has been implicated in promoting 
cell apoptosis and death through a conserved intracellular 
death domain (31-34). In the present study, we demonstrated 
that azacitidine was able to restore the expression of p75NTR 
in p75NTR-negative and aggressive prostate cancer (PCa) cell 
lines. This was dependent on increased p38 MAPK activa-
tion and the inhibition of DNMT actvitiy (35,36), and this 
was in agreement with a recent study in which estrogen and 
Figure 1. Antiproliferative and pro-apoptotic effects induced by azacitidine (5Aza-CR) at different concentrations in the presence or not of 10 ng/ml NGF. 
(A) (PC3) and (B) (22rv1) cells are subjected to the cytotoxic effects of different doses of azacitidine with or without NGF. (C) (PC3) and (D) (22rv1) cells 
undergo time-dependent apoptosis after treatment with a non-toxic concentration (0.5 µM) of azacitidine in combination with NGF. Data are representative 
of three independent replicates.
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Figure 2. Western blot analyses show a time-dependent induction of p75NTR and AR, but not TrkA expression, after in vitro administration of 0.5 µM azacitidine 
(Aza-CR) in PC3 (A) and 22rv1. (C) Immunocytochemical expression of p75NTR and AR in 22rv1 cells. (D) PC3 and (E) 22rv1 cells were examined for expres-
sion levels of downstream components proximal to p75NTR (TRADD, RIP, DR4, DR5 and TRAF2) after treatment with 0-5 µM azacitdine and 10 ng/ml NGF. 
(F) Immunohistochemical evaluation of p75NTR, TRADD and TRAL-R (DR4) in PC3 cell tumor-bearing nude mice treated or not with azacitidine (vidaza 
0.8 mg/kg/7 consecutive days). Each lane was loaded with 100 µg of proteins from the cell extracts obtained from the control and treated cells.
Figure 3. (A) Induction of pErk and p38 MAPK by ibuprofen in PC3 cells treated with 10 ng/ml NGF. (B) The p38 MAPK inhibitor, SB202190, reduced p75NTR 
expression. (C) Thus, we analyzed the role of p75NTR in azacitidine-induced cell death. For this aim we used a blocking antibody for p75NTR as well as the 
non-peptide antagonist of NGF, Ro 08-2750. Both anti-NGF agents significantly increased the cell viability (C) and apoptosis (D) induced by co-treatment of 
azacitidine (0.5 µM) and NGF (10 ng/ml). Each lane was loaded with 100 µg of proteins from the cell extracts obtained from control and treated cells. Data are 
representative of three independent replicates.
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azacitidine modulated the increased expression of p75NTR and 
apoptosis in 22rv1 cells (24). Previously, it has been shown that 
treatment with nonsteroidal anti-inflammatory drugs induces 
p75NTR expression leading to p75NTR-mediated decreased 
survival through a p38 MAPK-mediated mechanism (26-28). 
p38 MAPK could be a complementary mechanism by which 
prostate tumor cells re-express p75NTR. The re-expression of 
p75NTR tumor suppressor activity is associated with reduced 
tumor cell growth and activation of caspase 9-dependent 
caspase 3 activation. Since the re-expression of p75NTR does 
not alter levels of TrkA, these changes in cell cycle progres-
sion can be directly attributed to the changes in levels of the 
p75NTR protein. These effects were increased in the presence 
of NGF and indicate a TRAIL-mediated crosstalk with 
TRAILR (DR4) (37,38) or FAS:FASL signaling (39,40). In 
addition, cell cycle arrest, differentiation and apoptosis after 
p75NTR activation could involve further intracellular signals. 
It has been demonstrated that anti-inflammatory compounds 
modulate DNMT expression/activity (41,42) via phospholipase 
A2, able for example to induce cell arrest and differentiation 
in rat NK cells (43), and PPARγ activation (43) but not PPARβ, 
involved in differentiation of neuronal cells (44,45). In the 
absence of a ligand, p75NTR-dependent cell cycle arrest was 
accompanied by a rank-order increase in the apoptosis of PCa 
cells. NGF increased the apoptosis, via mitochondrial activation 
of a caspase cascade, induced by p75NTR re-expression. Taken 
together, it seems clear that p75NTR expression selectively alters 
specific cell cycle regulatory molecules that retard progression. 
In conclusion, the present study showed that p75NTR retards cell 
cycle progression and induces NGF-mediated apoptosis and 
suggests that the NGF network could be a candidate for future 
pharmacological manipulation for aggressive PCa.
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